

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
14 July 2005 (14.07.2005)

PCT

(10) International Publication Number
WO 2005/063755 A1

(51) International Patent Classification⁷: C07D 487/04,
A61K 31/495

Camino Real, San Diego, CA 92130 (US). ZHANG,
Xiahou [CN/US]; Neurocrine Biosciences Inc, 12790 El
Camino Real, San Diego, CA 92130 (US).

(21) International Application Number:

PCT/IB2004/004234

(22) International Filing Date:

20 December 2004 (20.12.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/532,031 22 December 2003 (22.12.2003) US

(71) Applicants (for all designated States except US): SB PHARMCO PUERTO RICO INC [US/US]; The Prentice Hall Corp System of PR Inc, c/o FGR Corporate Services Inc, BBV Tower 8th Floor, 254 Munoz Rivera Avenue, San Juan, Puerto Rico 00918 (US). NEUROCRINE BIOSCIENCES INC [US/US]; 12790 El Camino Real, San Diego, California 92130 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LUO, Zhiyong [CN/US]; Neurocrine Biosciences Inc, 12790 El Camino Real, San Diego, California 92130 (US). SLEE, Deborah [US/US]; Neurocrine Biosciences Inc, 12790 El Camino Real, San Diego, California 92130 (US). TELLEW, John, Edward [US/US]; Neurocrine Biosciences Inc, 12790 El Camino Real, San Diego, CA 92130 (US). WILLIAMS, John [US/US]; Neurocrine Biosciences Inc, 12790 El

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/063755 A1

(54) Title: CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO



(I)

(57) Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I), including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.